Becton, Dickinson and Company $BDX Shares Sold by Wilmington Savings Fund Society FSB

Key Points

• Wilmington Savings Fund Society FSB cut its stake in Becton, Dickinson and Company by 50.6%, reducing its holdings to 79,465 shares, valued at approximately $13.7 million.
• Several institutional investors have also increased or acquired stakes in Becton, Dickinson, indicating a significant interest, with 86.97% of the company's stock owned by institutional investors.
• Becton, Dickinson recently announced a quarterly dividend of $1.04 per share, reflecting a 2.2% dividend yield and a payout ratio of 74.82%.

Wilmington Savings Fund Society FSB lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 50.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 79,465 shares of the medical instruments supplier's stock after selling 81,475 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Becton, Dickinson and Company were worth $13,688,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Morningstar Investment Management LLC acquired a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $1,323,000. Axxcess Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 10.1% during the 2nd quarter. Axxcess Wealth Management LLC now owns 9,252 shares of the medical instruments supplier's stock valued at $1,594,000 after buying an additional 849 shares during the last quarter. Community Bank N.A. grew its holdings in Becton, Dickinson and Company by 10.9% during the 2nd quarter. Community Bank N.A. now owns 3,215 shares of the medical instruments supplier's stock valued at $554,000 after buying an additional 315 shares during the last quarter. NorthRock Partners LLC acquired a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $325,000. Finally, Verdence Capital Advisors LLC grew its holdings in Becton, Dickinson and Company by 10.3% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,806 shares of the medical instruments supplier's stock valued at $311,000 after buying an additional 168 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Up 0.1%

Shares of BDX opened at $186.76 on Tuesday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $53.53 billion, a P/E ratio of 33.59, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25. The stock's fifty day simple moving average is $190.23 and its 200 day simple moving average is $185.45. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last ninety days. Corporate insiders own 0.36% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on BDX shares. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price target on the stock. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.